May 10 |
EyePoint Pharmaceuticals Q1 2024 Earnings: Revenue Surpasses Estimates Despite Challenges
|
May 8 |
EyePoint Pharmaceuticals GAAP EPS of -$0.55 misses by $0.17, revenue of $11.68M beats by $2.54M
|
May 8 |
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
|
May 8 |
Flywire Reports Q1 Loss, Joins ZoomInfo, Inspire Medical Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
|
May 7 |
EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program
|
May 6 |
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
|
May 6 |
EyePoint tumbles 30% premarket on failed Phase 2 study
|
May 6 |
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
|
May 6 |
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYUâ„¢ in Non-Proliferative Diabetic Retinopathy
|
Apr 23 |
Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
|